The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera

Haematologica

Volumn 89, Issue 10, 2004, Pages 1264-1266

  Johansson, Peter ^a,b   Ricksten, Anne ^a   Wasslavik, Carina ^a   Johansson, Berit ^b   Andréasson, Björn ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Medicine ^*  (Sweden)

Author keywords

Hydroxyurea; Polycythemia rubra vera; PRV 1

Indexed keywords

HYDROXYUREA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; POLYCLONAL ACTIVATION; POLYCYTHEMIA VERA; PRV 1 GENE; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMPUTER SYSTEMS; FEMALE; HUMANS; HYDROXYUREA; ISOANTIGENS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLATELET COUNT; POLYCYTHEMIA VERA; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOCYTHEMIA, HEMORRHAGIC; UP-REGULATION;

EID: 6344253479     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000;95:2569-76.
2. Palmqvist L, Goerttler P, Wasslavik C, Johansson P, Andréasson B, Safai-Kutti S, et al. Comparison of methods for polycythemia rubra vera-1 mRNA quantification in whole-blood leukocytes and purified granulocytes. Clin Chem 2004;50:644-7.
3. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294-301.
4. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
5. Finazzi G, Barbui T. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathol Biol (Paris) 2001;49:167-9.
6. Livak K, Schmittgen T. Analysis of relative gene expression data using realtime quantitative PCR and the 2-AAC(T) method. Methods 2001;25:402-8.
7. Fruehauf S, Topaly J, Villalobos M, Veldwijk MR, Laufs S, Ho AD. Quantitative real-time polymerase chain reaction shows that treatment with interferon reduces the initially upregulated PRV-1 expression in polycythemia vera patients. Haematologica 2003;88:349-51.
8. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I. Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea. Ann Hematol 1995;71:119-21
9. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I. The in vitro and in vivo effect of recombinant interferon α-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 1994;87:621-3.
10. Wang M, Tang DC, Liu W, Chin K, Zhu JG, Fibach E, et al. Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. Br J Haematol 2002;119:1098-105.